Muscular dystrophies md pathology 10 marks question give beautiful answer to replicate
Reading File
Finding Sources
Searching Images
Duchenne muscular dystrophy muscle biopsy histology
Finding Sources
Reading File
Muscular Dystrophies - Pathology (10 Marks)
Definition
Muscular dystrophies are a group of inherited (genetically determined) disorders of skeletal muscle characterized by progressive degeneration and weakness of muscle fibers, usually becoming clinically evident after infancy. They result from mutations in genes coding for proteins of the dystrophin-glycoprotein complex, which links the muscle cytoskeleton to the extracellular matrix and maintains sarcolemmal integrity during contraction.
Classification
| Type | Inheritance | Gene/Protein Defect |
|---|---|---|
| Duchenne muscular dystrophy (DMD) | X-linked recessive | Dystrophin (absent) |
| Becker muscular dystrophy (BMD) | X-linked recessive | Dystrophin (reduced/abnormal) |
| Facioscapulohumeral dystrophy | Autosomal dominant | DUX4 derepression (4q35) |
| Myotonic dystrophy | Autosomal dominant | DMPK CTG repeat expansion |
| Limb-girdle dystrophies | AD/AR | Sarcoglycans, calpain, dysferlin, etc. |
| Congenital muscular dystrophies | Autosomal recessive | Laminin-α2 (merosin), others |
(Duchenne and Becker are the prototype dystrophinopathies and are the usual focus of a pathology exam answer.)
Etiopathogenesis of Duchenne/Becker Muscular Dystrophy
- Gene: DMD gene on Xp21, one of the largest human genes (2.3 million base pairs, 79 exons), encoding dystrophin.
- Duchenne MD: Frameshift/nonsense mutations → complete absence of dystrophin.
- Becker MD: In-frame deletions → reduced amount or abnormal (truncated) dystrophin, giving a milder phenotype.
- Normal function of dystrophin: Anchors the subsarcolemmal cytoskeleton (actin) to the dystrophin-associated glycoprotein complex in the sarcolemma, which in turn binds laminin in the extracellular matrix. This complex stabilizes the sarcolemma against the mechanical stress of repeated contraction-relaxation cycles.
- Consequence of deficiency: Sarcolemmal fragility → recurrent cycles of muscle fiber necrosis and regeneration → progressive fibrous and fatty replacement of muscle → weakness.
- Deficiency of dystrophin also destabilizes associated proteins (e.g., neuronal nitric oxide synthase, sarcoglycans), amplifying membrane instability and calcium influx-mediated fiber injury.
Morphology (Muscle Biopsy Findings)
- Variation in fiber size - abnormally large, rounded, hypercontracted fibers alongside small atrophic fibers.
- Segmental fiber necrosis with myophagocytosis (macrophages removing necrotic debris).
- Regenerating fibers - basophilic, with large nuclei and prominent nucleoli.
- Endomysial and perimysial fibrosis - progressive replacement of muscle by connective tissue.
- Fatty infiltration of muscle, most marked in advanced disease (produces the clinically apparent "pseudohypertrophy" of the calves).
- Immunohistochemistry: absent dystrophin staining on the sarcolemma in Duchenne MD; patchy/reduced staining in Becker MD.
- Late stage: "end-stage muscle" showing near-total replacement by fat and fibrous tissue with only scattered residual fibers.
Clinical Correlation
- Duchenne MD: Onset by age 1-5 years, progressive proximal (pelvic and shoulder girdle) weakness, calf pseudohypertrophy, Gower's sign, markedly elevated serum creatine kinase (CK), wheelchair-bound by early teens, death by 20s-30s from respiratory failure or dilated cardiomyopathy (cardiac muscle also expresses dystrophin).
- Becker MD: Later onset, slower progression, longer survival, milder cardiac involvement.
- Female carriers may show mild weakness or subclinical elevation of CK due to skewed X-inactivation.
Diagnosis
- Elevated serum CK (markedly high in Duchenne, less so in Becker).
- Genetic testing for DMD mutations (deletion/duplication analysis, sequencing).
- Muscle biopsy with dystrophin immunostaining/immunoblot when genetic testing is inconclusive.
- Electromyography shows a myopathic pattern (distinguishing from neurogenic disorders).
Summary Diagram (conceptual flow for answer)
Dystrophin gene mutation → Loss/reduction of dystrophin → Sarcolemmal instability → Repeated contraction-induced membrane damage → Fiber necrosis + attempted regeneration → Progressive fibrofatty replacement → Muscle weakness, pseudohypertrophy, cardiomyopathy.
Here is a biopsy image showing the classic Duchenne dystrophy findings for illustration in your answer sheet diagram:
(Note: I was unable to retrieve a verified image link from the library for this specific figure - for your written exam, simply sketch a labeled diagram showing: variable fiber size, necrotic fiber with macrophages, regenerating basophilic fiber, endomysial fibrosis, and fat replacement.)
Source: Robbins, Cotran & Kumar - Pathologic Basis of Disease (Pathogenesis of Dystrophinopathies), and Goldman-Cecil Medicine (Clinical Manifestations and Diagnosis, Dystrophinopathies section).
Quick evidence check: This is a well-established classical pathology topic with no significant recent evidence updates expected to change the core pathophysiology or histology described above, so no PubMed cross-check was necessary for this conceptual answer.
What about other question specifically asked muscular dystrophies
Asking for Preferences
Do you mean the exam question is worded simply as 'Muscular Dystrophies' (general, covering classification + all major types briefly), rather than a Duchenne-focused question like before?
Muscular Dystrophies - Pathology (10 Marks)
Definition
Muscular dystrophies are a group of inherited (genetically determined) disorders of skeletal muscle characterized by progressive degeneration and weakness of muscle fibers, usually becoming clinically evident after infancy. They result from mutations in genes coding for proteins of the dystrophin-glycoprotein complex, which links the muscle cytoskeleton to the extracellular matrix and maintains sarcolemmal integrity during contraction.
Classification
| Type | Inheritance | Gene/Protein Defect |
|---|---|---|
| Duchenne muscular dystrophy (DMD) | X-linked recessive | Dystrophin (absent) |
| Becker muscular dystrophy (BMD) | X-linked recessive | Dystrophin (reduced/abnormal) |
| Facioscapulohumeral dystrophy | Autosomal dominant | DUX4 derepression (4q35) |
| Myotonic dystrophy | Autosomal dominant | DMPK CTG repeat expansion |
| Limb-girdle dystrophies | AD/AR | Sarcoglycans, calpain, dysferlin, etc. |
| Congenital muscular dystrophies | Autosomal recessive | Laminin-α2 (merosin), others |
(Duchenne and Becker are the prototype dystrophinopathies and are the usual focus of a pathology exam answer.)
Etiopathogenesis of Duchenne/Becker Muscular Dystrophy
- Gene: DMD gene on Xp21, one of the largest human genes (2.3 million base pairs, 79 exons), encoding dystrophin.
- Duchenne MD: Frameshift/nonsense mutations → complete absence of dystrophin.
- Becker MD: In-frame deletions → reduced amount or abnormal (truncated) dystrophin, giving a milder phenotype.
- Normal function of dystrophin: Anchors the subsarcolemmal cytoskeleton (actin) to the dystrophin-associated glycoprotein complex in the sarcolemma, which in turn binds laminin in the extracellular matrix. This complex stabilizes the sarcolemma against the mechanical stress of repeated contraction-relaxation cycles.
- Consequence of deficiency: Sarcolemmal fragility → recurrent cycles of muscle fiber necrosis and regeneration → progressive fibrous and fatty replacement of muscle → weakness.
- Deficiency of dystrophin also destabilizes associated proteins (e.g., neuronal nitric oxide synthase, sarcoglycans), amplifying membrane instability and calcium influx-mediated fiber injury.
Morphology (Muscle Biopsy Findings)
- Variation in fiber size - abnormally large, rounded, hypercontracted fibers alongside small atrophic fibers.
- Segmental fiber necrosis with myophagocytosis (macrophages removing necrotic debris).
- Regenerating fibers - basophilic, with large nuclei and prominent nucleoli.
- Endomysial and perimysial fibrosis - progressive replacement of muscle by connective tissue.
- Fatty infiltration of muscle, most marked in advanced disease (produces the clinically apparent "pseudohypertrophy" of the calves).
- Immunohistochemistry: absent dystrophin staining on the sarcolemma in Duchenne MD; patchy/reduced staining in Becker MD.
- Late stage: "end-stage muscle" showing near-total replacement by fat and fibrous tissue with only scattered residual fibers.
Clinical Correlation
- Duchenne MD: Onset by age 1-5 years, progressive proximal (pelvic and shoulder girdle) weakness, calf pseudohypertrophy, Gower's sign, markedly elevated serum creatine kinase (CK), wheelchair-bound by early teens, death by 20s-30s from respiratory failure or dilated cardiomyopathy (cardiac muscle also expresses dystrophin).
- Becker MD: Later onset, slower progression, longer survival, milder cardiac involvement.
- Female carriers may show mild weakness or subclinical elevation of CK due to skewed X-inactivation.
Diagnosis
- Elevated serum CK (markedly high in Duchenne, less so in Becker).
- Genetic testing for DMD mutations (deletion/duplication analysis, sequencing).
- Muscle biopsy with dystrophin immunostaining/immunoblot when genetic testing is inconclusive.
- Electromyography shows a myopathic pattern (distinguishing from neurogenic disorders).
Summary Diagram (conceptual flow for answer)
Dystrophin gene mutation → Loss/reduction of dystrophin → Sarcolemmal instability → Repeated contraction-induced membrane damage → Fiber necrosis + attempted regeneration → Progressive fibrofatty replacement → Muscle weakness, pseudohypertrophy, cardiomyopathy.
Here is a biopsy image showing the classic Duchenne dystrophy findings for illustration in your answer sheet diagram:
(Note: I was unable to retrieve a verified image link from the library for this specific figure - for your written exam, simply sketch a labeled diagram showing: variable fiber size, necrotic fiber with macrophages, regenerating basophilic fiber, endomysial fibrosis, and fat replacement.)
Source: Robbins, Cotran & Kumar - Pathologic Basis of Disease (Pathogenesis of Dystrophinopathies), and Goldman-Cecil Medicine (Clinical Manifestations and Diagnosis, Dystrophinopathies section).
Quick evidence check: This is a well-established classical pathology topic with no significant recent evidence updates expected to change the core pathophysiology or histology described above, so no PubMed cross-check was necessary for this conceptual answer.
Finding Sources
Finding Sources
Finding Sources
Muscular Dystrophies - Pathology (10 Marks)
(This answer treats "Muscular Dystrophies" as a general/classification-based question - covering all major types with their genetics, pathogenesis, and morphology, rather than focusing only on Duchenne MD as in the previous answer. If your exam question is actually restricted to one type, let me know and I'll narrow it down.)
Definition
Muscular dystrophies (MDs) are a heterogeneous group of inherited disorders of skeletal muscle characterized by progressive muscle fiber degeneration, weakness, and wasting, resulting from mutations in genes encoding proteins that maintain the structural integrity of the muscle fiber membrane (sarcolemma) and its links to the cytoskeleton and extracellular matrix.
Classification (with Genetics & Pathogenesis)
1. Dystrophinopathies - Duchenne (DMD) & Becker (BMD)
- Inheritance: X-linked recessive; gene DMD on Xp21.
- Pathogenesis: Frameshift mutations → total absence of dystrophin (Duchenne, severe); in-frame deletions → truncated/reduced dystrophin (Becker, milder). Loss of dystrophin destabilizes the sarcolemma, making fibers susceptible to contraction-induced injury.
- Morphology: Fiber size variation, segmental necrosis with myophagocytosis, regenerating basophilic fibers, endomysial fibrosis, fatty replacement (calf pseudohypertrophy); absent/reduced dystrophin on immunostain.
- Clinical: Duchenne - onset 1-5 yrs, wheelchair-bound by teens, death from respiratory failure/dilated cardiomyopathy by 20s-30s, markedly raised CK. Becker - later onset, slower course, longer survival.
2. Myotonic Dystrophy (Steinert disease)
- Inheritance: Autosomal dominant.
- Type 1 (DM1): CTG trinucleotide repeat expansion in the 3' UTR of the DMPK gene on chromosome 19 (normal 5-30 repeats; affected 50-2000+). Shows genetic anticipation - repeat length increases and disease severity worsens/onset earlier in successive generations.
- Type 2 (DM2/PROMM): CCTG repeat expansion in the CNBP (ZNF9) gene.
- Mechanism: Expanded repeat RNA transcripts accumulate in the nucleus and sequester RNA-binding splicing factors (a "toxic RNA gain-of-function" mechanism), causing mis-splicing of multiple genes (including the muscle chloride channel, producing myotonia).
- Morphology: Ring fibers, increased central nuclei, selective type 1 fiber atrophy, sarcoplasmic masses.
- Clinical: Myotonia (delayed muscle relaxation), distal weakness (unlike proximal pattern in DMD), facial weakness/"hatchet face," ptosis, frontal balding, cataracts, cardiac conduction defects, testicular atrophy, congenital form in infants of affected mothers.
3. Facioscapulohumeral Dystrophy (FSHD)
- Inheritance: Autosomal dominant; third most common MD after Duchenne and myotonic dystrophy.
- Pathogenesis: Unique epigenetic mechanism - contraction of D4Z4 repeats at chromosome 4q35 (FSHD1) or SMCHD1 mutations (FSHD2) cause loss of normal repression (derepression) of the DUX4 gene, which is normally silenced in somatic tissue. Inappropriate DUX4 expression produces a toxic transcription factor in myofibers.
- Clinical: Facial weakness (unable to whistle/smile fully), scapular winging, proximal upper limb weakness, generally slowly progressive with normal lifespan.
4. Limb-Girdle Muscular Dystrophies (LGMD)
- Inheritance: Both autosomal recessive (more common, earlier onset) and autosomal dominant (milder) forms.
- Pathogenesis: Mutations in genes encoding sarcoglycans (α, β, γ, δ - components of the dystrophin-associated glycoprotein complex), calpain-3, dysferlin, and others - all disrupting the same sarcolemma-cytoskeleton-matrix linkage as in dystrophinopathies.
- Clinical: Proximal (pelvic and shoulder girdle) weakness, variable CK elevation, variable severity and cardiac/respiratory involvement depending on gene affected.
5. Congenital Muscular Dystrophies
- Inheritance: Mostly autosomal recessive.
- Pathogenesis: Defects in laminin-α2 (merosin) or in glycosylation of α-dystroglycan (dystroglycanopathies, e.g., POMT1, POMGnT1, fukutin-related protein mutations).
- Clinical: Present in infancy, often with associated CNS structural abnormalities (neuronal migration defects) and ocular involvement, in addition to progressive muscle weakness.
Common Unifying Pathologic Theme
Despite differing genes, most MDs converge on disruption of the dystrophin-glycoprotein-laminin axis (structural) or toxic RNA/protein accumulation (myotonic dystrophy, FSHD) → sarcolemmal fragility or cellular toxicity → repeated cycles of necrosis and regeneration → exhaustion of the regenerative (satellite cell) capacity → progressive fibrofatty replacement of muscle → weakness and, in cardiac/respiratory muscle, life-limiting complications.
Diagnostic Approach (common to all types)
- Serum CK (markedly elevated in DMD/BMD/LGMD; variable in myotonic dystrophy and FSHD).
- Electromyography - myopathic pattern (small, brief, polyphasic motor unit potentials).
- Muscle biopsy with histochemistry/immunohistochemistry (dystrophin, sarcoglycans) and electron microscopy.
- Molecular genetic testing - the definitive diagnostic tool in the current era (deletion/duplication analysis for DMD, repeat-primed PCR for DMPK/CNBP, D4Z4 repeat sizing for FSHD).
Sources: Robbins, Cotran & Kumar - Pathologic Basis of Disease (Pathogenesis of Muscular Dystrophies, Facioscapulohumeral Dystrophy sections); Robbins & Kumar Basic Pathology (Other X-Linked and Autosomal Muscular Dystrophies); Adams and Victor's Principles of Neurology (Myotonic Dystrophy, Limb-Girdle Muscular Dystrophies); Emery's Elements of Medical Genetics and Genomics (FSHD genetics); Goldman-Cecil Medicine (Other Muscular Dystrophies, Autosomal Dominant classification).
This is a stable, well-established pathology topic (classical genetics and histology unlikely to be contradicted by recent trials), so no PubMed evidence check was needed beyond the textbook synthesis above.
Combine all together
Muscular Dystrophies - Pathology (10 Marks) - Complete Answer
Definition
Muscular dystrophies (MDs) are a heterogeneous group of inherited disorders of skeletal muscle, characterized by progressive degeneration and weakness of muscle fibers usually becoming clinically evident after infancy. They result from mutations in genes coding for proteins that maintain the structural integrity of the sarcolemma and its link between the muscle cytoskeleton and the extracellular matrix - principally the dystrophin-glycoprotein complex.
Classification
| Type | Inheritance | Gene/Protein Defect |
|---|---|---|
| Duchenne muscular dystrophy (DMD) | X-linked recessive | Dystrophin (absent) |
| Becker muscular dystrophy (BMD) | X-linked recessive | Dystrophin (reduced/abnormal) |
| Myotonic dystrophy (DM1/DM2) | Autosomal dominant | CTG repeat in DMPK / CCTG repeat in CNBP |
| Facioscapulohumeral dystrophy (FSHD) | Autosomal dominant | DUX4 derepression (4q35 D4Z4 contraction) |
| Limb-girdle dystrophies (LGMD) | AD/AR | Sarcoglycans, calpain-3, dysferlin, etc. |
| Congenital muscular dystrophies | Autosomal recessive | Laminin-α2 (merosin), α-dystroglycan glycosylation defects |
Etiopathogenesis - Duchenne and Becker Dystrophies (Prototype, exam focus)
- Gene: DMD gene on Xp21, one of the largest human genes (2.3 million base pairs, 79 exons), encoding dystrophin.
- Duchenne MD: Frameshift/nonsense mutations → complete absence of dystrophin → severe phenotype.
- Becker MD: In-frame deletions → reduced or abnormal (truncated) dystrophin → milder phenotype.
- Normal function of dystrophin: Anchors the subsarcolemmal actin cytoskeleton to the dystrophin-associated glycoprotein complex (including sarcoglycans and dystroglycans) in the sarcolemma, which binds laminin in the extracellular matrix, stabilizing the membrane against the mechanical stress of repeated contraction-relaxation cycles.
- Consequence of deficiency: Sarcolemmal fragility → recurrent cycles of fiber necrosis and regeneration → progressive fibrous and fatty replacement of muscle → weakness. Loss of dystrophin also destabilizes associated proteins (e.g., neuronal nitric oxide synthase, sarcoglycans), amplifying membrane instability and calcium-mediated fiber injury.
Morphology (Muscle Biopsy)
- Marked variation in fiber size - large, rounded, hypercontracted fibers alongside small atrophic fibers.
- Segmental fiber necrosis with myophagocytosis (macrophage-mediated clearance of debris).
- Regenerating fibers - basophilic, with large nuclei and prominent nucleoli.
- Progressive endomysial and perimysial fibrosis.
- Fatty infiltration, most marked in advanced disease (clinical correlate: calf pseudohypertrophy).
- Immunohistochemistry: dystrophin absent from the sarcolemma in Duchenne MD; patchy/reduced staining in Becker MD.
- End stage: near-total replacement of muscle by fat and fibrous tissue with scattered residual fibers.
Clinical Correlation
- Duchenne MD: onset age 1-5 years, proximal (pelvic/shoulder girdle) weakness, calf pseudohypertrophy, Gower's sign, markedly elevated serum CK, wheelchair-bound by early teens, death by 20s-30s from respiratory failure or dilated cardiomyopathy (cardiac muscle also expresses dystrophin).
- Becker MD: later onset, slower progression, longer survival, milder cardiac involvement.
- Female carriers may show mild weakness/subclinical CK elevation due to skewed X-inactivation.
Other Major Types (Brief Pathogenesis)
Myotonic dystrophy (Steinert disease) - autosomal dominant. DM1 is caused by a CTG trinucleotide repeat expansion in the 3' UTR of DMPK on chromosome 19 (normal 5-30 repeats; affected 50 to several thousand), showing genetic anticipation (repeat size and severity increase across generations). DM2 involves a CCTG expansion in CNBP. Mechanism is a toxic RNA gain-of-function: expanded repeat transcripts accumulate in the nucleus and sequester RNA-splicing factors, causing mis-splicing of multiple genes including the muscle chloride channel (producing myotonia). Morphology shows ring fibers, increased central nuclei, and selective type 1 fiber atrophy. Clinically: myotonia, distal (not proximal) weakness, facial weakness/ptosis, frontal balding, cataracts, cardiac conduction defects, testicular atrophy.
Facioscapulohumeral dystrophy (FSHD) - autosomal dominant; third most common MD. Unique epigenetic mechanism: contraction of D4Z4 repeats at chromosome 4q35 (or SMCHD1 mutation) causes derepression of the normally silenced DUX4 gene, producing a toxic transcription factor in myofibers. Clinically causes facial weakness, scapular winging, and proximal arm weakness with a generally slow course and normal lifespan.
Limb-girdle muscular dystrophies (LGMD) - autosomal recessive (more common, earlier/severe) or dominant (milder). Caused by mutations in sarcoglycans, calpain-3, dysferlin, and other proteins of the dystrophin-glycoprotein complex, producing a similar proximal (pelvic/shoulder girdle) weakness pattern to dystrophinopathies.
Congenital muscular dystrophies - autosomal recessive, present in infancy, due to laminin-α2 (merosin) deficiency or defective glycosylation of α-dystroglycan; often associated with CNS neuronal migration defects and ocular abnormalities in addition to muscle weakness.
Unifying Pathologic Concept
Most MDs converge on disruption of the dystrophin-glycoprotein-laminin axis (structural dystrophies) or toxic RNA/protein accumulation (myotonic dystrophy, FSHD), leading to sarcolemmal fragility or cellular toxicity, repeated necrosis-regeneration cycles, eventual exhaustion of satellite cell regenerative capacity, and progressive fibrofatty replacement of muscle - producing weakness and, when cardiac/respiratory muscle is involved, life-limiting complications.
Diagnosis (applicable across types)
- Serum CK - markedly elevated in DMD, less so in BMD/LGMD, variable in myotonic dystrophy/FSHD.
- Electromyography - myopathic pattern (small, brief, polyphasic motor unit potentials).
- Muscle biopsy with histochemistry/immunohistochemistry (dystrophin, sarcoglycans) ± electron microscopy.
- Molecular genetic testing - now the definitive tool (deletion/duplication analysis of DMD; repeat-primed PCR for DMPK/CNBP; D4Z4 repeat sizing for FSHD).
Sources: Robbins, Cotran & Kumar - Pathologic Basis of Disease (Pathogenesis of Muscular Dystrophies, Dystrophinopathies, Facioscapulohumeral Dystrophy); Robbins & Kumar Basic Pathology (Other X-Linked and Autosomal Muscular Dystrophies); Adams and Victor's Principles of Neurology (Myotonic Dystrophy, Limb-Girdle Muscular Dystrophies); Emery's Elements of Medical Genetics and Genomics (FSHD genetics); Goldman-Cecil Medicine (Dystrophinopathies, Other Muscular Dystrophies).
Diagram tip for exam: draw the sarcolemma with dystrophin linking subsarcolemmal actin to the sarcoglycan/dystroglycan complex and laminin in the basal lamina - label where DMD/BMD (dystrophin), LGMD (sarcoglycans), and congenital MD (laminin-α2/dystroglycan glycosylation) mutations act along this axis.
This is a shared conversation. Sign in to Orris to start your own chat.